Endocarditis, Bacterial Clinical Trial
Official title:
Neurological Complication of Infective Endocarditis: A Prospective Multi-site Cohort Study With Systematic MRI and Digital Subtraction Angiography
The main objective of this study is to better estimate the rate of infectious intracranial aneurysms (IIA) in proved infective endocarditis (IE). It also aims to identify MRI markers capable of accurately predicting (or excluding) IIA; to assess the impact of the different MRI abnormalities on the outcome; to capture the real-world management of EI with neurological complications in comprehensive IE centers in France
Rationale: The incidence of Infective endocarditis (IE) in developed countries is approximately 3-15 per 100,000 pers-years. Discharge mortality remains 15-30% and therapeutic management suffers in many ways from the paucity of randomized studies.(1) Symptomatic neurological complications, which occur in 15 to 30% of patients, are the most frequent extra-cardiac complication of IE and are deemed to worsen the outcome of EI.(2,3) Among this overall neurological complications, Infectious Intracranial Aneurysms (IIA) are a relatively rare, yet probably underestimate, vessel wall injury caused by septic emboli, with potentially intracranial bleeding for the patients. Neuroimaging in the context of IE has gained wide acceptance and is encouraged in the current guidelines.(4,5) Nevertheless the benefit of early neuroimaging to optimize the initial therapeutic management remains debated.(6,7) While the appearance and the frequency of the various neurologic complications of EI are well known thanks to prospective cohort studies with systematic pre-therapeutic MRI(8-10), several clinically relevant questions are still unknow or approximate, including: 1/ What is the rate of IIA in proved EI. The current gold standard for the detection of these small and distally located aneurysms remains Digital Subtraction Angiography (DSA) and to our knowledge, there is no prospective unbiased cohort of IE with systematic DSA available in the literature. 2/ Are there MRI signs correlated with the presence of IIA on DSA? Several MRI markers such as sulcal SWI lesion or cerebral microbleeds (CMBs) with contrast enhancement look promising (10), but validation in unbiased prospective studies with systematic MRI and DSA is needed. 3/ What is the impact on the outcome of the different MRI abnormalities and of unruptured and ruptured IIA? As previously mentioned, the value of both MRI and DSA remain unclear to guide the acute therapeutic management of EI. A recent French survey highlighted differences between university Hospital in France in the management of IIA. Thus, the analysis of the current management of EI with neurological complications could also help at informing the design of future randomized trials. Questions: 1. Better estimate the rate of IIA in proved EI. 2. Identify MRI markers able to accurately predict (or exclude) IIA. 3. What is the impact of different MRI abnormalities on the outcome? 4. Capture the real-world management of EI with neurological complications in comprehensive EI centers in France Design and setting: Multi-site, prospective cohort study, with standardized imaging protocol, in academic centers where MRI and DSA are performed routinely in patients with EI. Ethics: As for all non-interventional studies of de-identified data, written informed consent will be waived and a commitment to compliance (Reference Methodology CPMR-4) will be filed to the French data protection authority (CNIL) prior to data centralization, in respect to the General Data Protection Regulation. Patients and proxies will be informed they could oppose the use of their data for research purposes. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00401960 -
Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.
|
Phase 4 | |
Terminated |
NCT00695903 -
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
|
Phase 2 | |
Recruiting |
NCT05644990 -
T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
|
||
Recruiting |
NCT04840225 -
Anemia in Patients With Endocarditis
|
||
Completed |
NCT00524212 -
How to Improve Diagnosis in Infective Endocarditis
|
N/A | |
Completed |
NCT03048643 -
Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis
|
N/A | |
Completed |
NCT00144885 -
IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis
|
N/A | |
Completed |
NCT03306225 -
Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients
|
||
Active, not recruiting |
NCT05522764 -
Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
|
||
Terminated |
NCT04222257 -
Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis
|
Phase 4 | |
Not yet recruiting |
NCT05613933 -
Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and/or History of Infective Endocarditis
|
N/A | |
Recruiting |
NCT02979951 -
Fosfomycin i.v. for Treatment of Severely Infected Patients
|
||
Active, not recruiting |
NCT06434012 -
Barts Endocarditis Research Registry
|
||
Recruiting |
NCT06250985 -
New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System
|
Phase 3 |